COMPAZINE
LOE ApproachingNDAORALSYRUP
Approved
Dec 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMPAZINE (prochlorperazine) is an oral syrup small-molecule antipsychotic and antiemetic approved in 1957 by GSK. The drug's exact mechanism of action and approved indications are not specified in available data, but it is a legacy phenothiazine class agent. It is used to manage nausea, vomiting, and potentially psychiatric symptoms in select patient populations.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a transition team focused on lifecycle extension and generic mitigation strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
COMPAZINE currently has zero linked open positions, reflecting its LOE-approaching lifecycle stage and mature market status. Roles on this product typically focus on line maintenance, generic defense, and operational efficiency rather than growth or innovation.
Brand ManagerCommercial Operations
Worked on COMPAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.